Medacta Group Reports Remarkable 18.5% Revenue Growth in 2025

Medacta Group SA announced a robust 18.5% growth in constant currency for 2025, with total revenue reaching EUR 683.8 million. This reflects the company's continued above-market performance across all business lines and geographic areas. The successful integration of Parcus Medical contributed a modest 1.5% boost to this growth.

Growth was significant across regions, with the highest increases in Asia Pacific at 23%, followed by North America at 19%. Latin America, although the smallest segment, displayed outstanding growth of 42.2% in constant currency.

Product lines also performed well. Knee revenues surged by 20.7%, driven by Medacta’s personalized platforms and innovative implants. The Extremities segment, especially shoulders and sports medicine, saw a remarkable 46.2% rise. Hip and Spine lines also recorded notable gains.

These figures underscore Medacta's strategic focus on differentiating innovations, such as their minimally invasive techniques and personalized surgical solutions, which continue to drive their growth.